Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Site-specific targeting in immunoliposomal nanomedicine for oncology: opportunities and limitations | Synapse
March 3, 2026
Site-specific targeting in immunoliposomal nanomedicine for oncology: opportunities and limitations
MM
M. Milczarek
Narodowy Instytut Leków
PK
P. Kleczkowska
Puntos clave
Targeting strategies improve drug delivery in oncology, enhancing therapeutic outcomes while reducing side effects.
Important metrics indicate that tumor localization increases effectiveness by up to 80% over conventional methods.
Analysis on treatment regimens explores immunoliposomal applications in various cancer types and their unique targeting capabilities.
Supports the need for further research to validate these approaches in clinical settings; external validation is essential.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Milczarek et al. (Fri,) studied this question.
synapsesocial.com/papers/69a768a6badf0bb9e87e577c
https://doi.org/https://doi.org/10.1016/j.ejpb.2026.115004